

April 7, 2008  
AnGes MG, Inc.

**Medical Use Patent on NF- B Decoy-Oligo Granted in Europe – Covering Its Use  
for Atopic Dermatitis**

We, AnGes MG, are pleased to announce that our medical use patent on NF- B decoy-oligo, for use in the treatment of atopic dermatitis, was granted in Europe, with the patent gazette (EP1362600B1) published on April 2.

This patent covers extensive uses of NF- B decoy-oligo in the form of preparations for topical (percutaneous) application for the treatment of atopic dermatitis. It will powerfully support our project on NF- B decoy in Europe for a long period of time.

This invention has already been patented in Japan. Patent applications have also been filed with many other countries, including the USA, to cover our initiatives of global development.

In addition to this patent, our company plans to file applications for patents related to the use of NF- B decoy-oligo for other diseases such as asthma, aneurysm, organ/blood vessel transplantation, psoriasis, rheumatoid arthritis, bone formation, and so on, with the goal of establishing our intellectual proprietary rights corresponding to our strategy of expanding clinical applications.

Furthermore, our patent covering the use of this compound for treatment of inflammatory disease, ischemic heart disease, autoimmune disease, cancer metastasis/invasion or cachexia has already been granted in Europe (EP0824918B1).

We are currently developing NF- B decoy-oligo as a means of treating atopic dermatitis in Japan. We have licensed its development in Europe and the USA to Meyer Pharmaceuticals, LLC.